RBC Capital reiterated an Outperform rating and $247 price target on Illumina (ILMN) after Roche (RHHBY) presented scientific details about its ...

UBS analyst Matthew Weston upgraded Roche Holding (OTC:RHHBY) stock from Neutral to Buy, adjusting the price target to CHF 338.00, up from the previous CHF 300.00. The upgrade comes as the stock ...

We recently published a list of 10 Best Annual Dividend Stocks To Buy Now. In this article, we are going to take a look at ...

Piper Sandler analyst maintains an Overweight rating on Teva, citing positive feedback on duvakitug's potential in treating IBD. Nabaparna Bhattacharya Sarepta Therapeutics' Duchenne Gene Therapy ...

BofA lowered the firm’s price target on Illumina (ILMN) to $90 from $110 and keeps an Underperform rating on the shares. Shares have fallen 25% ...

RHHBY has been the subject of a number of research ... Hancock Whitney Corp now owns 23,516 shares of the company’s stock valued at $820,000 after acquiring an additional 1,496 shares during ...

Assess today's live Roche Holding Ltd DRC (RHHBY) share price, performance and insights using our live OTC Markets: RHHBY stock exchange data. Analyse the historical data and Roche Holding Ltd DRC ...

Shares of OTCMKTS RHHBY opened at $41.29 on Wednesday. The company has a debt-to-equity ratio of 0.86, a quick ratio of 0.97 and a current ratio of 1.26. Roche has a one year low of $29.20 and a ...

The tablet can be swallowed whole or dispersed in water. PFE, NVS and ABBV have a Zacks Rank #3 (Hold) each, while Sanofi and RHHBY have a Zacks Rank #4 (Sell) each. You can see the complete list ...